The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2022 | Combining CAR-Ts & bispecific antibodies
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, describes an approach to combine chimeric antigen-receptor T-cells (CAR-Ts) with bispecific antibodies to improve patient outcomes. Using different adapters such as bispecific antibodies binding to both a CAR-T and a target antigen, it is possible to target several antigens in parallel or sequentially. In addition, the short half-life of bispecific antibodies enables CAR-Ts to be switched on and off easily, thereby improving the tolerability of CAR-Ts. Early data is suggesting this as a promising approach, but it is necessary to further evaluate it in a larger number of patients. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
